Treatment of systemic lupus erythematosus patients with the BAFF antagonist “peptibody” blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials

INTRODUCTION: Blisibimod is a potent B cell-activating factor (BAFF) antagonist that binds to both cell membrane-expressed and soluble BAFF. The goal of these first-in-human studies was to characterize the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of blisibimod in subjec...

Descripción completa

Detalles Bibliográficos
Autores principales: Stohl, William, Merrill, Joan T., Looney, R. John, Buyon, Jill, Wallace, Daniel J., Weisman, Michael H., Ginzler, Ellen M., Cooke, Blaire, Holloway, Donna, Kaliyaperumal, Arunan, Kuchimanchi, Kameswara Rao, Cheah, Tsui Chern, Rasmussen, Erik, Ferbas, John, Belouski, Shelley S., Tsuji, Wayne, Zack, Debra J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545922/
https://www.ncbi.nlm.nih.gov/pubmed/26290435
http://dx.doi.org/10.1186/s13075-015-0741-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545922/
https://www.ncbi.nlm.nih.gov/pubmed/26290435
http://dx.doi.org/10.1186/s13075-015-0741-z

Ejemplares similares